Concomitant medication, comorbidity and survival in patients with breast cancer

Elise Dumas, Beatriz Grandal Rejo, Paul Gougis, Sophie Houzard, Judith Abécassis, Floriane Jochum, Benjamin Marande, Annabelle Ballesta, Elaine Nery, Thierry Dubois, Samar Alsafadi, Bernard Asselain, Aurélien Latouche, Marc Espie, Enora Laas, Florence Coussy, Clémentine Bouchez, Jean-Yves Pierga, Christine Bihan-Benjamin, Philippe-Jean Bousquet, Judicaël Hotton, Chloé-Agathe Azencott, Fabien Reyal () and Anne-Sophie Hamy
Additional contact information
Elise Dumas: Université Paris Cité
Beatriz Grandal Rejo: Université Paris Cité
Paul Gougis: Université Paris Cité
Sophie Houzard: Health Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa)
Judith Abécassis: Université Paris Cité
Floriane Jochum: Université Paris Cité
Benjamin Marande: Université Paris Cité
Annabelle Ballesta: PSL Research University
Elaine Nery: PICT-IBISA, PSL Research University
Thierry Dubois: Institut Curie - PSL Research University Translational Research Department Breast Cancer Biology Group 26 rue d’Ulm
Samar Alsafadi: PSL Research University, Uveal Melanoma Group, Translational Research Department
Bernard Asselain: Unicancer
Aurélien Latouche: U900
Marc Espie: Université Paris Cité
Enora Laas: Université Paris Cité, Institut Curie
Florence Coussy: Université Paris Cité, Institut Curie
Clémentine Bouchez: Université Paris Cité
Jean-Yves Pierga: Université Paris Cité, Institut Curie
Christine Bihan-Benjamin: Health Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa)
Philippe-Jean Bousquet: Équipe Labellisée Ligue Contre le Cancer
Judicaël Hotton: Institut Jean Godinot
Chloé-Agathe Azencott: U900
Fabien Reyal: Université Paris Cité
Anne-Sophie Hamy: Université Paris Cité

Nature Communications, 2024, vol. 15, issue 1, 1-15

Abstract: Abstract Between 30% and 70% of patients with breast cancer have pre-existing chronic conditions, and more than half are on long-term non-cancer medication at the time of diagnosis. Preliminary epidemiological evidence suggests that some non-cancer medications may affect breast cancer risk, recurrence, and survival. In this nationwide cohort study, we assessed the association between medication use at breast cancer diagnosis and survival. We included 235,368 French women with newly diagnosed non-metastatic breast cancer. In analyzes of 288 medications, we identified eight medications positively associated with either overall survival or disease-free survival: rabeprazole, alverine, atenolol, simvastatin, rosuvastatin, estriol (vaginal or transmucosal), nomegestrol, and hypromellose; and eight medications negatively associated with overall survival or disease-free survival: ferrous fumarate, prednisolone, carbimazole, pristinamycin, oxazepam, alprazolam, hydroxyzine, and mianserin. Full results are available online from an interactive platform ( https://adrenaline.curie.fr ). This resource provides hypotheses for drugs that may naturally influence breast cancer evolution.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-47002-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47002-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-47002-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().